At a glance

Our pivotal position in the rapidly evolving regenerative medicine field is supported by a group of leading investors. Through the significant funding we have raised and the continual development of our pipeline of novel tissue-specific cellular medicines, we are well positioned to push the frontiers of science and innovation in regenerative medicine. 

Our Releases

Our releases

CTA approval for potentially pivotal HeartcelTM Phase IIb trial
Stratford-upon-Avon, 08/01/2018

World Leading Cardiac Specialists Join Celixir Scientific Advisory Board to Form Innovative Cardiovascular Medicines Collaboration
Cardiff , 17/08/2016

Celixir Partners with TMC Life Sciences Bhd and Thomson to Change the Standard of Medical Care for Patients in Southeast Asia.
Cardiff, 05/08/2016

Cell Therapy Rebrands as Celixir
CARDIFF, 20/07/2016

Cell Therapy Ltd Grants Japan License To Daiichi Sankyo For Its Heart Regeneration Medicine, Heartcel™
Cardiff, 10/05/2016

Cell Therapy Ltd announces positive Phase II clinical trial results of Tendoncel™, a first-in-class topical regenerative medicine for severe tendon injury
Cardiff, 30/06/2015

Cell Therapy Ltd announces continuing 100% MACE-free survival after two years average follow up in the Heartcel™ clinical trial in advanced heart failure patients at high risk of incomplete revascularization
Cardiff, 24/06/2015

Cell Therapy Ltd to submit Heartcel™ for conditional marketing authorisation post meeting with the European Medicines Agency
Cardiff, 10/05/2015


1 2 3Next
1 2 3Next
Presentations

Presentations

11th World Congress of Regenerative Medicine & Stem Cell, Singapore Date: 16 November 2017

“Celixir's Phase IIb/ Phase III Regenerative Medicine Clinical Trials.”

Biotech Roundtable, London UK

“The differences in culture of institutional biotech investors in Europe versus the US, and how that impacts the ability of individual biotechs to grow and commercialise.”

    Date: 10 May 2017

European Business Development Conference, Germany Date: 28 September 2016

“Introduction to cell & gene therapy” and “Topic Based Partnering”

European Society of Gene and Cell Therapy Conference (ESGCT 2016)

Florence, 18 to 21 October 2016

    Presentation by Celixir:

    • Fixing the So-called Unfixable: Regenerating Untreatable Fixed Myocardial Scar in Heart Failure Patients; A. Reginald, S. Sultan, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis

    Celixir posters:

    • Immunomodulatory Progenitor Cells: A Novel And Safe Allogeneic Therapy For Patients With Ischaemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting; S. Sultan, A. Reginald, L. Chapman, M. Evans, K, P. Antonitsis, S. Westaby and K. Anastasiadis

    • Tendoncel Phase II Placebo Controlled Randomized Clinical Trial Results For A Novel Allogeneic Regenerative Topical Medicine In Treatment Of Chronic Tendon Injury; A. Reginald, S. Sultan, A. Mousiadou, L. Chapman, M. Evans & G. Panagiotis

International Congress of the European Society for Cardiovascular and Endovascular Surgery, 26th-29th March 2015, Istanbul, Turkey (ESCVS 2015)

Celixir studies presented:

    • ESCVS 2015 Roberts et al. Myocardial Regeneration with Cell Therapy – Heartcel™
The Biology of Regenerative Medicines, 22-24 April 2015, Cambridge, UK

Celixir studies presented:

    • The Biology of Regenerative Medicines 2015 Sultan et al. Isolation of iMP Cells of Mesodermal Lineage From Healthy Peripheral Blood
British Society for Gene and Cell Therapy Annual Conference, 9th-11th June 2015, Strathclyde, Glasgow (BSGCT 2015)

Celixir studies presented:

    • BSGCT 2015 Sultan et al. Isolation of iMP Cells A Novel and Distinct Mesodermal Progenitor Cell
The International Society for Stem Cell Research Annual Meeting, 24th-27th June 2015, Stockholm, Sweden (ISSCR 2015)

Celixir studies presented:

    • ISSCR 2015 Sultan et al. Immunomodulatory Progenitor Cells A Novel Allogeneic Therapy for Patients with Ischaemic Cardiomyopathy undergoing CABG
    • ISSCR 2015 Sultan et al. Isolation of Immunomodulatory Progenitor Cells A Novel and Distinct Mesodermal Progenitor Cell
    • ISSCR 2015 Sultan et al. Tendoncel™ Phase II Placebo controlled Randomized Clinical Trial results of a novel allogeneic regenerative topical medicine in treatment of Chronic Tendon injury
4th International Conference and Exhibition on Cell & Gene Therapy, August 10-12, 2015, London (CGT 2015)

Celixir studies presented:

    • CGT 2015 Reginald et al. A Double Blind Randomised Placebo Controlled Phase IIb Clinical Trial to Study the Efficacy and Safety of Tendoncel™ in Lateral Epicondylitis
European Society of Gene and Cell Therapy Congress, 17-20 September 2015, Helsinki, Finland (ESGCT 2015)

Celixir studies presented:

    • ESGCT 2015 Reginald et al. Tendoncel™ Phase II Placebo controlled Randomized Clinical Trial results of a novel allogeneic regenerative topical medicine in treatment of Chronic Tendon injury
    • ESGCT 2015 Sultan et al. Isolation of immunomodulatory progenitor cells of mesodermal lineage
    • ESGCT 2015 Sultan et al. Immunomodulatory progenitor cells- a novel allogeneic therapy for patients with ischaemic cardiomyopathy undergoing coronary artery bypass grafting

Factsheets and infographics

Factsheets and infographics

Following are a range of factsheets and infographics for media and other background use – check back soon as we are always adding to our library.

Media enquiries

Investor Enquiries

For investor enquiries please contact:

investors@celixir.com